Involvement of the Genetic Diversity of HIV-1 in the Virological Treatment Failure of First Line Antiretroviral in Kinshasa — Oak Academic Publishing
Research ArticleOpen AccessGoogle Scholar indexed
Involvement of the Genetic Diversity of HIV-1 in the Virological Treatment Failure of First Line Antiretroviral in Kinshasa
Molecular Biology Unit, Department of Basic Sciences, Faculty of Medicine, University of Kinshasa (UNIKIN), Kinshasa, Democratic Republic of Congo (DRC)
,
Molecular Biology Unit, Department of Basic Sciences, Faculty of Medicine, University of Kinshasa (UNIKIN), Kinshasa, Democratic Republic of Congo (DRC)
,
Molecular Biology Unit, Department of Basic Sciences, Faculty of Medicine, University of Kinshasa (UNIKIN), Kinshasa, Democratic Republic of Congo (DRC)
,
AIDS Reference Laboratory (ARL), Centre Hospitalier Universitaire-Université de Liège (CHU-Lg), Liège, Belgium
,
AIDS Reference Laboratory (ARL), Centre Hospitalier Universitaire-Université de Liège (CHU-Lg), Liège, Belgium
,
Clinical Microbiology Laboratory, Centre Hospitalier Universitaire-Université de Liège (CHU-Lg), Liège, Belgium
1 Molecular Biology Unit, Department of Basic Sciences, Faculty of Medicine, University of Kinshasa (UNIKIN), Kinshasa, Democratic Republic of Congo (DRC)
2 Molecular Biology Unit, Department of Basic Sciences, Faculty of Medicine, University of Kinshasa (UNIKIN), Kinshasa, Democratic Republic of Congo (DRC)
3 Molecular Biology Unit, Department of Basic Sciences, Faculty of Medicine, University of Kinshasa (UNIKIN), Kinshasa, Democratic Republic of Congo (DRC)
4 AIDS Reference Laboratory (ARL), Centre Hospitalier Universitaire-Université de Liège (CHU-Lg), Liège, Belgium
5 AIDS Reference Laboratory (ARL), Centre Hospitalier Universitaire-Université de Liège (CHU-Lg), Liège, Belgium
6 Clinical Microbiology Laboratory, Centre Hospitalier Universitaire-Université de Liège (CHU-Lg), Liège, Belgium
Background: Genetic diversity of human immunodeficiency virus affects the treatment and the emergence of resistance. Some subtypes would develop resistance more frequently than others. The aim of this study is to determine the rate of virological treatment failure and the involvement of genetic diversity and different mutations in this failure in Kinshasa. Methods: Of the 153 Antiretroviral-naive patients who were included in the cohort, 138 patients have been received for the appointment of the 6 th month. Clinical parameters were recorded on individual patient charts. The determination of Viral Load (VL) was done at the Laboratory of Molecular Biology. Clinical and biological parameters of the 6 th month were compared with those taken at baseline of the cohort to determine the evolution of patients under treatment. Results: At the consultation of the 6 th month, 138 patients (90.2%) had returned out of the 153 included. Eighty-one (58.7%) patients were women and 57 (41.3%) men. The age of patients is between 18 and 65 with an average of 37 years. Ten deaths (6.5%) and 5 (3.3%) lost have been reported. One hundred twenty-five patients (90.5%) were in clinical stage 3 and 13 (9.5%) in clinical stage 4. The median CD4 T cells is 560 cells mm 3 . The median VLs of patients was 0.90 log 10 RNA copies/ml. Of the 34 patients in virological failure, 8 (23.5%) are minimal failure, 23 (67.7%) in moderate failure and 3 (8.8%) in severe failure. According to the Pearson’s test, VLs at 6 th months were highly correlated with that of inclusion, with V75 and K70 mutations for NRTIs, with V108 mutation for NNRTI well as the virological failure of treatment. Conclusion: Our results confirmed the hypothesis that high Viral Load at the start of the treatment is a poor prognosis for the development of therapy. Transmitted mutations are involved in treatment failure.
Kamangu, N.E., Kabututu, Z.P., Mvumbi, L.G., Kalala, L.R. and Mesia, K.G. (2013) Genetic Diversity of Human Immunodeficiency Virus Type 1 in the Democratic Republic of Congo: A Review of Available Data. International Journal of Collaborative Research on Internal Medicine and Public Health, 5, 295-309.
Kandathil, A.J., Ramalingam, S., Kannagai, R., David, S. and Sridharan, G. (2005) Molecular Epidemiology of HIV. Indian Journal of Medical Research, 121, 333-344.
Takebe, Y., Kusagawa, S. and Motomura, K. (2004) Molecular Epidemiology of HIV: Tracking AIDS Pandemic. Pediatrics International, 46, 236-244. https://doi.org/10.1046/j.1442-200x.2004.01869.x
Thomson, M.M. and Nájera, R. (2005) Molecular Epidemiology of HIV-1 Variants in the Global AIDS Pandemic: An Update. AIDS Reviews, 7, 210-224.
Etienne, L. and Peeters, M. (2010) Origine du VIH, une réussite émergentielle. Virologie, 14, 171-183.
Hemelaar, J., Gouws, E., Ghys, P.D. and Osmanov, S. (2006) Global and Regional Distribution of HIV-1 Genetic Subtypes and Recombinants in 2004. AIDS, 20, W13-W23. https://doi.org/10.1097/01.aids.0000247564.73009.bc
Shao, Y. and Williamson, C. (2012) The HIV-1 Epidemic: Low- to Middle-Income Countries. Cold Spring Harbor Perspectives in Medicine, 2, a007187. https://doi.org/10.1101/cshperspect.a007187
Coffin, J.M. (1995) HIV Population Dynamics in Vivo: Implications for Genetic Variation, Pathogenesis, and Therapy. Science, 267, 483-489. https://doi.org/10.1126/science.7824947
Eshleman, S.H., Becker-Pergola, G., Deseyve, M., Guay, L.M., Mracna, M., Fleming, T., Cunningham, S., Musoke, P., Mmiro, F. and Jackson, J.B. (2001) Impact of Human Immunodeficiency Virus Type 1 (HIV-1) Subtype on Women Receiving Single-Dose Nevirapine Prophylaxis to Prevent HIV-1 Vertical Transmission (HIV Network for Prevention Trials 012 Study). The Journal of Infectious Diseases, 184, 914-917. https://doi.org/10.1086/323153
Brenner, B., Turner, D., Oliveira, M., Moisi, D., Detorio, M., Carobene, M., Marlink, R.G., Schapiro, J., Roger, M. and Wainberg, M.A. (2003) A V106M Mutation in HIV-1 Clade C Viruses Exposed to Efavirenz Confers Cross-Resistance to Non-Nucleoside Reverse Transcriptase Inhibitors. AIDS, 17, F1-F5. https://doi.org/10.1097/00002030-200301030-00001
Loemba, H., Brenner, B., Parniak, M.A., Ma’ayan, S., Spira, B., Moisi, D., Oliveira, M., Detorio, M. and Wainberg, M.M.A. (2002) Genetic Divergence of Human Immunodeficiency Virus Type 1 Ethiopian Clade C Reverse Transcriptase (RT) and Rapid Development of Resistance against Nonnucleoside Inhibitors of RT. Antimicrobial Agents and Chemotherapy, 46, 2087-2094. https://doi.org/10.1128/AAC.46.7.2087-2094.2002
Delfraissy, J.F. (2005) Prise en charge thérapeutique des personnes infectées par le VIH. Rapport 2004, Médecine-Sciences, Flammarion.
Kamangu, N.E., Kawila, M.E., Mukumbi, H. and Mvumbi, L.G. (2012) Estimated Rates of Treatment Failure in First-Line Antiretroviral Treatment in Kinshasa: Case of the ACS AMO-Congo. International Journal of Collaborative Research on Internal Medicine and Public Health, 4, 885-891.
Programme National de Lutte contre le VIH/SIDA et les Infections Sexuellement Transmissible (PNLS), Ministère de la Santé Publique, République Démocratique du Congo (RDC) (2013) Guide National de Prise en Charge de l’Infection à VIH en RDC. Version révisé.
Kamangu, N.E., Chatte, A., Susin, F., Boreux, R., Kalala, L.R., Mvumbi, L.G., De Mol, P., Vaira, D. and Hayette, M.P. (2015) Genetic Diversity and Antiretroviral Drug Resistance among Drug-Naive HIV Type 1 Infected Patients Attending Clinics in Kinshasa, Democratic Republic of Congo. Journal of HIV and AIDS, 1.
Kamangu, N.E., Bulanda, I.B., Bongenia, I.B., Botomwito, T.H., Mvumbi, L.G., De Mol, P., Vaira, D., Hayette, M.P. and Kalala, L.R. (2015) Virological Profile of Patients Infected with HIV Starting Antiretroviral Treatment in Kinshasa. Open Access Library Journal, 2, e1564. https://doi.org/10.4236/oalib.1101564
Kamangu, N.E., Chatte, A., Boreux, R., Kalala, L.R., Mvumbi, L.G., De Mol, P., Vaira, D. and Hayette, M.P. (2014) Implementation of an In-House Quantitative Real-Time PCR for Determination of HIV Viral Load in Kinshasa. Open Access Library Journal, 1, e855. https://doi.org/10.4236/oalib.1100855
Kamangu, N., Chatte, A., Boreux, R., Kalala, L.R., Mvumbi, L.G., Vaira, D. and Hayette, M.P. (2014) Mise en place d’une PCR Quantitative Temps Réel pour la détermination de la Charge Virale VIH à Kinshasa. Journal des Recherches BioMédicales, 1, 7-12.
Kamangu, N.E., Chatte, A., Boreux, R., Susin, F., Kalala, L.R., Mvumbi, L.G., De Mol, P., Hayette, M.P. and Vaira, D. (2015) Comparison of an In-House Quantitative Real Time PCR and COBAS AmpliPrep/TaqMan Roche for Determination of Viral Load for HIV Type 1 Non-B. Open Access Library Journal, 2, e1402. https://doi.org/10.4236/oalib.1101402
Morlat, P. (sous la direction de) (2014) Prise en Charge Médicale des Personnes Vivant avec le VIH: Recommandations du Groupe d’experts. Sous l’égide du CNS et de l’ANRS. Rapports 2013.
Yéni, P. (sous la direction de) (2010) Prise en charge médicale des personnes infectées par le VIH. Recommandations du groupe d’Experts. Médecine Sciences, Flammarion, Paris.
Kamangu, N.E., Situakibanza, N.H., Mvumbi, L.G., Kakudji, I.L., Tshienda, T.D. and Mesia, K.G. (2012) Infections Opportunistes chez les Personnes Vivant avec le VIH suivi à l’Hopital Militaire de Référence de Kinshasa (Camp Kokolo). Revue Congolaise des Sciences, 1, 66-76.
Bongenya, B., Ilombo, L., Botomwito, H., Bulanda, B., Kamangu, E., Lusakibanza, M. and Mesia, G. (2014) Fréquence du Suivi des Paramètres Biologiques des Patients sous Antirétroviraux à Kinshasa: Cas de l’Hopital Provincial Général de Référence. Journal des Recherches BioMédicales, 1, 1-6.
Kamangu, N.E., Kalala, N.H. and Mesia, K.G. (2012) Profile of Antiretroviral Treatment Centers in Kinshasa, Democratic Republic of Congo [Poster 388]. Proceedings of the 1st International African Society of Laboratory Medicine (ASLM) Conference, Cape Town, 1-7 December 2012, 377.
Muwonga, J., Edidi, S., Butel, C., Vidal, N., Monleau, M., Okenge, A., Mandjo, J.L., Mukumbi, H., Muyembe, J.J., Mbayo, F., Kayembe, D., Delaporte, E., Boillot, F. and Peeters, M. (2011) Resistance to Antiretroviral Drugs in Treated and Drug-Naive Patients in the Democratic Republic of Congo. Journal of Acquired Immune Deficient Syndrome, 57, S27-S33. https://doi.org/10.1097/QAI.0b013e31821f596c
Egger, M., May, M. and Chêne, G. (2002) Prognosis of HIV-1-Infected Patients Starting Highly Active Therapy: A Collaborative Analysis of Prospective Studies. The Lancet, 360, 119-129. https://doi.org/10.1016/S0140-6736(02)09411-4
Phair, J.P., Mellors, J.W., Detels, R., Margolick, J.B. and Munoz, A. (2002) Virologic and Immunologic Values Allowing Safe Deferral of Antiretroviral Therapy. AIDS, 16, 2455-2459. https://doi.org/10.1097/00002030-200212060-00011
Anejo-Okopi, J.A., Agbaji, O.O., Agaba, P.A., Ugoagwu, P.O., Were, K., Onywera, H., Owiti, P., Isa, S.E., Otecko, N., Okwori, A.E.J., Musa, J., Oguche, S., Sagay, A.S., Idoko, J.A., Nimzing, L., Jatau, E.D. and Olonitola, O.S. (2013) Human Immunodeficiency Virus Type 1 (HIV-1) Genetic Diversity and Prevalence of Antiretroviral Drug Resistance Mutations in Treatment-Naive Adults in Jos, North Central Nigeria. African Journal of Biotechnology, 12, 2279-2287. https://doi.org/10.5897/AJB2013.11954
Afonso, J.M., Bello, G., Guimaraes, M.L., Sojka, M. and Morgado, M.G. (2012) HIV-1 Genetic Diversity and Treatment Drug Resistance Mutations among Patients from North, Central and South Regions of Angola. PLoS ONE, 7, e42996. https://doi.org/10.1371/journal.pone.0042996
Santos, A.F. and Soares, M.A. (2010) HIV Genetic Diversity and Drug Resistance. Virus, 2, 503-531. https://doi.org/10.3390/v2020503